Jeff Evanson, Chief Commercial Officer at Outlook Therapeutics, Inc. (OTLK), sold 267,000 shares at $1.11 ($296K) on 2023-01-20, disclosed to the SEC on 2023-01-24.
Open-market sale of $296k OTLK by Chief Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| OTLK | BUY | 2021-12-06 | $47K | — | Filing → |
| OTLK | SELL | 2021-02-25 | $18K | — | Filing → |
| OTLK | SELL | 2021-02-17 | $291K | — | Filing → |